Crinetics Pharmaceuticals, Inc. — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2021-02-26

Reporting Person: Madan Ajay (Chief Development Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-26	Stock Option (right to buy)	$15.29	A	131000	Acquired	2031-02-25	Common Stock (131000)	Direct

Footnotes

F1: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021.